Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan.
The drug has been backed by the Japanese Ministry of Health, Labour & Welfare to treat some sufferers of colorectal cancer, Tokyo-based Takeda said.
‘The approval is based primarily on the results of the Fresco-2 trial, a global phase 3 clinical trial conducted in the United States, Europe, Japan and Australia. The trial compared Fruzaqla plus best supportive care with placebo plus BSC in patients with previously treated metastatic colorectal cancer. The Fresco-2 trial met all primary and key secondary efficacy endpoints and demonstrated consistent benefits in patients who received Fruzaqla, regardless of the types of therapy the patients had previously received,’ Takeda said.
London-listed Hutchmed China Ltd, which in China develops and markets fruquintinib, the generic name of Fruzaqla, noted the announcement.
The Hong Kong-based biopharmaceutical company said the approval demonstrates ‘the strength of our global data package and the potential of this novel medicine’.
Takeda shares closed down 0.4% to JP¥4,258 each in Tokyo on Tuesday. Hutchmed was up 1.2% at 256.00 pence each in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
